TITLE

Finally. a drug for Alzheimer's

AUTHOR(S)
Rubin, Rita; Silver, Marc
PUB. DATE
September 1993
SOURCE
U.S. News & World Report;9/20/93, Vol. 115 Issue 11, p83
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
States that Tacrine, the first medication approved by the US Food and Drug Administration to ward off the symptoms of Alzheimer's disease, should soon be available. Number of Americans that suffer from the disease; Brand name Cognex; Side effects.
ACCESSION #
9309160029

 

Related Articles

  • Immunotherapeutic Strategies for Prevention and Treatment of Alzheimer's Disease. Solomon, Beka // DNA & Cell Biology;Nov2001, Vol. 20 Issue 11, p697 

    Pathologic examination in Alzheimer's disease (AD) shows a significant correlation between β-amyloid peptide (AβP) deposition and the clinical severity of dementia. Formation of β-amyloid (Aβ) is a complex kinetic and thermodynamic process, dependent on peptide–peptide...

  • Taking good care of the caregiver.  // Executive Health's Good Health Report;Apr92, Vol. 28 Issue 7, p8 

    Comments on the impact of caring for a parent with Alzheimer's disease, senile dementia and similar conditions on the caregiver. Disruption to personal and family life; Some things that may help the caregiver including individual and family counseling, support groups and alternative solutions...

  • Alzheimers treatment tested in Tucson.  // Inside Tucson Business;10/14/2002, Vol. 12 Issue 29, p19 

    Reports on the clinical test for the treatment of Alzheimer's disease at the Neurological Associates of Tucson in Arizona. Use of the COGNIShunt System for treating the disease; Design of the system; Phases of the clinical trials.

  • HRSA awards $3.9 million for Alzheimer's projects.  // Public Health Reports;Mar/Apr93, Vol. 108 Issue 2, p263 

    States the Health Resources and Services Administration (HRSA) of the Public Health Service has announced a $3.9 million Alzheimer's Demonstration Grant to States Program to provide services, develop projects and disseminate information to people with Alzheimers disease, their caregivers and...

  • What exercise can do for Alzheimer's.  // RN;Oct92, Vol. 55 Issue 10, p101 

    Reports that taking Alzheimer's patients for regular walks may improve their communication skills, suggest two nurse researchers. Rita Friedman and Ruth M. Tappen; Highlights of the research; Originally published in the `Journal of the American Geriatrics Society,' volume 39 issue 7.

  • Benefits of tacrine for Alzheimer's patients challenged. Davis, K.; Thal, L. // RN;Jan93, Vol. 56 Issue 1, p93 

    Features a study of the effects of tacrine on patients with Alzheimer's disease, published in the New England Journal of Medicine. Doses given for a six-week trial; Results of mental performance testing; List of limitations.

  • Alzheimer's disease: Gaining attention for a good reason. Southwick, Karen // Managed Healthcare;Feb98, Vol. 8 Issue 2, p50 

    Discusses developments in the process of providing therapy for persons with Alzheimer's disease in the United States. Steps undertaken by Warner-Lambert Co.'s Cognex and Pfizer Inc.'s Aricept in solving the disease; Increase in managed care's participation in Medicare risk contracts; Suggested...

  • New Alzheimer's drug.  // Consumer Reports on Health;Apr97, Vol. 9 Issue 4, p41 

    Reports on the approval of donepezil (Aricept) for the treatment of Alzheimer's diseases. Previous approval of tacrine (Cognex); Fewer side effects of donepezil.

  • A `small group' approach to Alzheimer's care. Henry, Linda J. // Nursing Homes: Long Term Care Management;Mar94, Vol. 43 Issue 2, p50 

    Describes the Small Group Program of the Sunset Manor Alzheimer's Care Center in Brush, Colorado. Program structure; Criteria for resident selection for the program; Program objectives; Training and orientation of group leaders handling the program; Adaptability of the structure with the...

  • Anti-inflammatory may offer hope for symptoms of Alzheimer's.  // Geriatrics;Nov93, Vol. 48 Issue 11, p31 

    Discusses the potential of the nonsteroidal anti-inflammatory drug indomethacin in protecting Alzheimer's disease patients from the degree of cognitive decline exhibited by those receiving placebo. Improvement on several cognitive measures exhibited by patients receiving indomethacin; Analysis...

Share

Read the Article

Other Topics